International legal practice Osborne Clarke has advised Bone Therapeutics on its acquisition of a majority stake in Medsenic. This combination of Bone Therapeutics and Medsenic has created a new biopharma company, BioSenic.

The combination of the two companies will significantly delineate and expand Bone Therapeutics' therapeutic portfolio, which targets a broad range of inflammatory and orthopaedic indications. The two companies are currently conducting several mid- to late-stage clinical trials in lupus, chronic graft-versus-host disease, tibial fractures and other indications.

Bone Therapeutics said in a statement:

Combining these clinical development programmes within a single entity would therefore offer a number of economic, financial and operational benefits and synergies"

This transaction demonstrates Osborne Clarke's capacity to advise on complex ECM M&A transactions. The Belgian team was led by partner Hadrien Chef and included partner David Haex and the following associates: Violette Keppenne, Tonya Aelbrecht, Laurent De Pauw and Shahine Kalantari. They worked in collaboration with Osborne Clarke in Paris with partner Catherine Olive and associate Cyrille d'Amécourt.

Corporate communications and press contacts

If you are a journalist and would like comment or background from our legal experts, we can help. Our team will put you in touch with the best person. View a full list of our international press contacts by jurisdiction here.